Table 2.

Characteristics and symptom changes in patients with PASC receiving Low Dose Naltrexone (0.5–6 mg) by the duration of infection.

	>=365 days	<365 days	P-value
Cases	28 (47.5%)	31 (52.5%)
Number of symptoms at baseline	14.5 [9, 16.25], 13.107*	14 [8.5, 15.5], 13.032	0.790
Days since infection	514 [469, 615], 533	273 [146, 329], 244
Age	44 [33, 54.25], 44.89	50 [35, 60.5], 48.58	0.425
Female	22 (78.6%)	18 (58.1%)	0.105
Days on LDN**	133 [70, 162], 137	168 [86, 343], 217	0.083
Change in number of symptoms	−1 [−4, 0], −1.46	−2 [−4.5, 0], −2.74	0.368
Change in Fatigue	−1 [−1, 0], −0.61	0 [−1.5, 1], −0.52	0.495
Change in Brain fog	0 [−1,0.25], −0.29	0 [−1, 0], −0.42	0.729
Change in Post exertional malaise ***	0 [−1, 0], −0.43	0 [−1.5, 0], −0.81	0.789
Change in Unrefreshing sleep	0 [−2, 0], −0.82	0 [−1.5, 0.5], −0.45	0.351
Change Abnormal sleep pattern	−1 [−2.25, 0], −0.86	0 [−2, 0], −0.58	0.695
Change in Headache	−0.5 [−1, 0], −0.39	0 [−1, 1], 0.000	0.333
Change in Lightheadedness	0 [0, 0.25], 0.00	0 [−1, 0.5], −0.42	0.393

^*Median [inter-quartiles] mean;

^**Low Dose Naltrexone;

^***Post Exertional Mala